RhoD Immunoglobulin and Anemia in Pregnancy

A medication used to prevent Rh incompatibility in pregnant women with Rh-negative blood.

RhoD immunoglobulin is typically administered between 26 to 28 weeks of pregnancy.

Used during birth or events causing maternal-fetal blood mixing, like trauma or amniocentesis.

The standard dose of RhoD immunoglobulin is 300 micrograms via intramuscular injection.

A blood test that quantifies fetal red blood cells in maternal circulation to guide RhoD dosing.

Both reproductive partners must be Rh-negative for offspring to be Rh-negative, eliminating the need for RhoD.

RhoD immunoglobulin must be given within 72 hours after potential exposure for best results.

Hemoglobin value above 15 grams/dL or hematocrit above 45% indicates potential issues in pregnancy.

Elevated hemoglobin/hypotonicity can cause hypertension and poor perinatal outcomes.

Anemia reduces maternal blood's oxygen-carrying capacity affecting fetus oxygen supply.

Anemia types that are genetic can lead to fetal growth restriction and early pregnancy loss.

Up to 40% of maternal deaths in developing countries linked to anemia, particularly blood loss.

Most common form of anemia impacting pregnancy and perinatal health.

Anemia may increase a woman's likelihood of preterm birth due to oxygen deficiencies.

Chronic low oxygen levels in fetus can lead to stress and early labor initiation.

Anemia is categorized as acquired or hereditary, influencing health outcomes during pregnancy.

An autoimmune disorder causing blood clots and pregnancy complications.

Repeated unexplained pregnancy loss before 20 weeks.

Inherited condition leading to increased risk of venous clots due to genetic mutations.

Anticoagulation treatment used in managing antiphospholipid syndrome during pregnancy.

Monitoring of fetal growth and well-being during high-risk pregnancies.

A genetic disorder affecting red blood cell function, leading to hemolytic anemia under certain conditions.

Medications that can trigger hemolysis in individuals with G6PD deficiency, including sulfonamides and nitrofurantoin.

A mode of inheritance where the gene causing a trait or disorder is located on the X chromosome, affecting more males than females.

Anemia that results from the destruction of red blood cells, leading to a deficiency in their number.

A genetic condition affecting erythrocyte shape, leading to fragile spherical red blood cells and hemolytic anemia.

Testing done to determine if a partner carries a genetic mutation that could affect fetal health, particularly in known conditions like G6PD deficiency.

Anomalies in fetal development that may occur due to maternal health issues like new G6PD deficiency diagnosis during pregnancy.

Health issues that exist before pregnancy, which may complicate maternal and fetal health such as G6PD deficiency.

Genetic defects affecting the structure of red blood cell membranes, leading to conditions like spherocytosis.

Protocols developed for managing specific health conditions, which ensure consistent and safe care.

A type of hemoglobin increased in thalassemia, normally below 3.5%.

Fetal hemoglobin, typically greater than 2% in thalassemia patients.

Severe cases often lead to infertility in affected women.

Routine monitoring for growth and complications during pregnancy.

Recommended to support hemoglobin levels in pregnancy.

Used to enhance oxygen-carrying capacity of hemoglobin chains.

Recommended due to the inheritable nature of thalassemia.

Possibility of having multiple thalassemia traits, complicating the condition.

Severe form of alpha thalassemia leading to sterility and fetal issues.

Severe form resulting in reduced life expectancy and infertility.